AN ACT to amend Tennessee Code Annotated, Title 56 and Title 71, relative to coverage of biomarker testing.
The introduction of SB 435 is anticipated to significantly impact state health laws by standardizing insurance coverage for biomarker testing across health benefit plans. This move aims to ensure that all patients within Tennessee have equitable access to advanced medical testing, which is increasingly vital in precision medicine. In addition to promoting better healthcare outcomes, the bill may also improve treatment efficacy through tailored therapies that utilize biomarker information, thereby optimizing resource use in the healthcare system.
Senate Bill 435, sponsored by Senator Reeves, seeks to amend the Tennessee Code Annotated concerning health insurance coverage for biomarker testing. The bill mandates that health insurers, effective January 1, 2026, must include coverage for biomarker testing within their health benefit plans. Biomarker testing is defined as the analysis of a patient’s biospecimen, such as blood or tissue, for indicators related to normal biological processes or responses to therapies. The intention behind this legislation is to facilitate enhanced diagnostic and treatment measures tailored to individual patient needs based on their unique biomarker profiles.
While the bill has garnered support for its potential to improve treatment outcomes and patient care, it may also face challenges related to the costs associated with implementing widespread coverage for biomarker testing. Insurance companies could express concerns regarding the financial implications of mandated coverage, particularly the potential for increased premium costs. Additionally, the need for regulatory adherence and ensuring that testing follows established medical and scientific evidence may invoke discussions on the adequacy of existing guidelines and protocols related to biomarker testing.